Pioglitazone
CAS No. 111025-46-8
Pioglitazone( U-72107 )
Catalog No. M10411 CAS No. 111025-46-8
Pioglitazone is a selective peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist, used to treat diabetes.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 32 | In Stock |
|
| 10MG | 43 | In Stock |
|
| 25MG | 57 | In Stock |
|
| 50MG | 88 | In Stock |
|
| 100MG | 129 | In Stock |
|
| 500MG | 317 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePioglitazone
-
NoteResearch use only, not for human use.
-
Brief DescriptionPioglitazone is a selective peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist, used to treat diabetes.
-
DescriptionPioglitazone is a selective peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist, used to treat diabetes.(In Vitro):Pioglitazone (0.5 or 1 μM, 5 days) can completely prevent AGEs (advanced glycation end-products)-induced β-cell necrosis and the increase of caspase-3 thereby avoiding the impaired viability caused by AGEs in pancreatic beta cell line HIT-T15.Pioglitazone (1 μM, 1 h) can stimulate insulin secretion induced by low glucose concentration and attenuate the GSSG/GSH ratio in cells cultured with AGEs.(In Vivo):Pioglitazone (oral gavage, 10 or 30 mg/kg, once daily, 14 days) can induce improvements in insulin resistance and diabetes that may be lipocalin-dependent in the liver but not in skeletal muscle.Pioglitazone (oral gavage, 10 mg/kg, once daily, 4 weeks) can significantly reduce body weight (BW), cardiac hypertrophy, elevated blood glucose levels and improve the associated dyslipidemia.
-
In Vitro——
-
In VivoAnimal Model:ob/ob and adipo-/- ob/ob mice with a C57Bl/6 backgroundDosage:10 or 30 mg/kgAdministration:Oral gavage; once daily; 14 daysResult:Showed no changes of serum-free fatty acid and triglyceride levels as well as adipocyte sizes in ob/ob and adipo-/- ob/ob C57BL/6 mice at 10 mg/kg but significantly reduced to a similar degree at 30 mg/kg.Also showed no changes of expressions of TNFα and resistin in adipose tissues of ob/ob and adipo-/- ob/ob mice at 10 mg/kg but decreased at 30 mg/kg.Animal Model:Male Wistar albino rats Dosage:10 mg/kg Administration:Oral gavage; once daily; 4 weeks Result:Decreased the elevated serum levels of both creatinine and creatine kinase-MB (CK-MB), TGF-β1 gene expression and regulated the expression of MMP-2/TIMP-2 system.
-
SynonymsU-72107
-
PathwayMetabolic Enzyme/Protease
-
TargetPPAR
-
RecptorPPAR
-
Research AreaInflammation/Immunology
-
Indication——
Chemical Information
-
CAS Number111025-46-8
-
Formula Weight356.44
-
Molecular FormulaC19H20N2O3S
-
Purity>98% (HPLC)
-
SolubilityDMSO: 15 mg/mL (42.08 mM)
-
SMILESO=C(C(S1)CC(C=C2)=CC=C2OCCC3=NC=C(CC)C=C3)[N]C1=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Jaakkola T, et al. Basic Clin Pharmacol Toxicol. 2006 Jul;99(1):44-5
molnova catalog
related products
-
Rosiglitazone
A potent and selective PPARγ agonist that binds to the PPARγ ligand-binding domain with a Kd of 40 nM.
-
Pioglitazone hydroch...
Pioglitazone hydrochloride can increase both insulin-stimulated glucose uptake in peripheral tissues and insulin sensitivity in hepatic and adipose tissue.
-
Furegrelate sodium
Furegelate sodium is a selective thromboxane synthase inhibitor with oral activity.
Cart
sales@molnova.com